An economic evaluation of first-line cryoballoon ablation vs antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a U.S. Medicare perspective
Oussama M. Wazni, Joe W. E. Moss, Malte Kuniss, Jason G. Andrade, Gian‐Battista Chierchia, Stuart Mealing, Waruiru Mburu, Alicia Sale, Rachelle Elizabeth Kaplon, Eleni Ismyrloglou, Tom Bromilow, Emily Lane, Damian Lewis, Matthew R. Reynolds
Journal
- ISSN / E-ISSN
- — / —
- DOI
- 10.1016/j.hroo.2023.07.007 ↗
- Volume · Issue · Pages
- 4 · 9 · 528-537
- Publisher
- Elsevier Ltd.
- Article URL
- https://doi.org/10.1016/j.hroo.2023.07.007 ↗
- Article details
- Unverified
Publication date (each date has its type and source)
27 Jul 2023
OpenAlex publication date · source: OpenAlex
| Type | Date | Source |
|---|---|---|
| OpenAlex publication date | 27 Jul 2023 | OpenAlex |
Keywords (as given): paroxysmal atrial fibrillation; cryoballoon ablation; antiarrhythmic drugs; cost-effectiveness; Medicare; rhythm control; quality-adjusted life years; incremental cost-effectiveness ratio; atrial arrhythmia recurrence
HEC Status at Publication Not the journal's current status
HEC Status at PublicationConclusive
HEC status at publication
Recognized
X
Based on the recorded HEC dataset applicable to the article's publication date. Listed as X in the HEC list for 2023–24.
- Journal
- Heart Rhythm O2
- Publication date used
- 27 Jul 2023 (OpenAlex publication date)
- Applicable HEC period
- 2023–24 (version 1) · 01 Jul 2023 – 30 Sep 2024
- Category
- X
- Recognition status
- Recognized (OK_RECORD_FOUND)
- Source
- HJRS 2023-24 page 1713, row 12129
- Verification status
- Verified against source · last verified 23 Sep 2026
This is an automatically generated summary based on the information available on the publication date. Terms & conditions apply.